



10 December 2024

Our Ref: FOI 150

Dear

**Freedom of Information Act 2000
Information in relation to Migraine Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 4 October 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Surgery & Elective, Maternity & Paediatrics Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. Please provide the number of migraine patients treated in the last 4 months with:

- ***Atogepant (Aquipta)***
- ***Erenumab (Aimovig)***
- ***Eptinezumab (Vypti)***
- ***Fremanezumab (Ajovy)***
- ***Galcanezumab (Emgality)***
- ***Rimegepant (Vydura)***
- ***Botulinum Toxin (i.e., Botox, Dysport, Xeomin)***

Q2. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

- ***Atogepant***
- ***Erenumab***
- ***Eptinezumab***
- ***Fremanezumab***
- ***Galcanezumab***
- ***Rimegepant***
- ***Botulinum Toxin***

Q3. How many patients have you treated in the last 4 months for acute migraine with:

- ***Rimegepant (Vydura)***

Q4. Are you required to complete Blueteq for the following product classes:

- ***Botulinum Toxin (Botox, Dysport, Xeomin)***
- ***Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)***
- ***Gepants (e.g. rimegepant, atogepant)***

A1-4. In response to questions 1 to 4, due to the new digital system, the information that you have requested is not centrally held in a way which is easily extracted. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice.